Overview

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Status:
NOT_YET_RECRUITING

Trial end date:
2034-10-31

Target enrollment:

Participant gender:

Summary

This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).

Phase:

PHASE2

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

lenvatinib